Key result
Cryoballoon ablation shows similar 6-month atrial tachyarrhythmia recurrence versus high-power short-duration ablation in paroxysmal AF.
Why the study?
HPSD and CBA are both used for PVI, but a direct comparison of their efficacy in patients with PAF was needed.
Does cryoballoon ablation compared to high-power short-duration radiofrequency ablation improve efficacy and reduce recurrence in patients with paroxysmal atrial fibrillation?
Observational (n=251)
Does cryoballoon ablation compared to high-power short-duration radiofrequency ablation improve efficacy and reduce recurrence in patients with paroxysmal atrial fibrillation?
Absolute Event Rate: 11% vs 14.5%
p-value: p=0.40
Cryoballoon ablation and high-power short-duration radiofrequency ablation have comparable 6-month efficacy for paroxysmal AF, though cryoballoon ablation achieves faster pulmonary vein isolation.
Comparable 6-month efficacy in this cohort should not yet change practice; leaves open need for randomized trials of cryoballoon versus high-power short-duration ablation.
BACKGROUND: High-power short-duration (HPSD) and cryoballoon ablation (CBA) has been used for pulmonary vein isolation (PVI). OBJECTIVE: We aimed to compare the efficacy of PVI between CBA and HPSD ablation in patients with paroxysmal atrial fibrillation (PAF). METHODS: We retrospectively analyzed 251 consecutive PAF patients from January 2018 to July 2020. Of them, 124 patients (mean age 57.2 ± 10.1 year) received HPSD and 127 patients (mean age 59.6 ± 9.4 year) received CBA. In HPSD group, the radiofrequency energy was set as 50 W/10 s at anterior wall and 40 W/10 s at posterior wall. In CBA group, 28 mm s generation cryoballoon was used for PVI according the guidelines. RESULTS: There was no significant difference in baseline characteristics between these 2 groups. The time to achieve PVI was significantly shorter in cryoballoon ablation group than in HPSD group (20.6 ± 1.7 min vs 51.8 ± 36.3, P = 0.001). The 6-month overall recurrence for atrial tachyarrhythmias was not significantly different between the two groups (HPSD:14.50% vs CBA:11.0%, P = 0.40). There were different types of recurrent atrial tachyarrhythmia between these 2 groups. Recurrence as atrial flutter was significantly more common in CBA group compared to HPSD group (57.1% vs 12.5%, P = 0.04). CONCLUSION: In PAF patients, CBA and HPSD had a favourable and comparable outcome. The recurrence pattern was different between CBA and HPSD groups.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2023) conducted an observational in Paroxysmal atrial fibrillation (PAF) (n=251). Cryoballoon ablation (CBA) vs. High-power short-duration (HPSD) ablation was evaluated on 6-month overall recurrence for atrial tachyarrhythmias (p=0.40). Cryoballoon ablation resulted in similar 6-month recurrence of atrial tachyarrhythmias compared to high-power short-duration ablation in paroxysmal atrial fibrillation (11.0% vs 14.5%, P=0.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: